Interventional Spine announces first US implant of Renew to treat lumbar spinal stenosis

857

Interventional Spine recently announced the first commercial implant in the United States of its Renew interspinous allograft technology for the treatment of lumbar spinal stenosis. The Renew implant is an interspinous process device made from allograft for the treatment of lumbar spinal stenosis. Designed for maximum ease to implant, and to provide a more “natural” interference within the spinous process, the company believes that this innovative device will improve outcomes and provide cost efficiency to hospitals and surgeons alike.

The Renew implant is available in six different sizes to accommodate the patient’s anatomy. The company believes that the market exceeds $400 million in the United States and intends to begin a limited product launch of the product in June 2010, with a full US launch by the end of 2010. Interventional Spine believes that the implant will be a major contributor to revenue growth in 2011 and 2012.

 

The first implant was performed at the Inova Fairfax Hospital in Fairfax, Virginia by Ronald C Childs. Upon completing the procedure, Childs commented: “I am very pleased with this product. The use of the Renew implant provides, in my view, a welcomed alternative to the other various interspinous process devices made from synthetic materials presently on the market.”

Walter A Cuevas, Chief Executive Officer of Interventional Spine said: “The Renew implant, made from human allograft, has some key patented attributes which make it unique among other interspinous implants.”